Long-term debt · 2018–2025
Castle Biosciences long-term debt
$9.6M−1.1% · FY2025
Castle Biosciences (CSTL) reported $9.6M in long-term debt for fiscal 2025, −1.1% year on year.
Long-term debt — Long-term debt is borrowing due more than a year out. A large figure is normal for capital-intensive businesses and says nothing on its own about financial health.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2025 compound annual growth −12.5%
Long-term debt at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Castle Biosciences long-term debt |url=https://companiesranked.com/en/company/castle-biosciences/long-term-debt |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Castle Biosciences long-term debt. CompaniesRanked. https://companiesranked.com/en/company/castle-biosciences/long-term-debtBibTeX
@misc{companiesranked-en-company-castle-biosciences-long-term-debt-2026,
author = {{CompaniesRanked}},
title = {{Castle Biosciences long-term debt}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/castle-biosciences/long-term-debt}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0001628280-26-051052 · July 30, 2026
{{cite web |title=Castle Biosciences long-term debt — 10-Q (0001628280-26-051052) |url=https://www.sec.gov/Archives/edgar/data/1447362/000162828026051052/cstl-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-30}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.